{"entity": "journal", "iuid": "688187b8bcd04a648207c3c24e1f89e4", "timestamp": "2026-09-03T05:16:05.579Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/journal/Clin%20Lung%20Cancer.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/journal/Clin%20Lung%20Cancer"}}, "title": "Clin Lung Cancer", "issn": "1938-0690", "issn-l": null, "publications_count": 2, "publications": [{"entity": "publication", "iuid": "d5ec1a6bfece4461aca4245d1ba015ac", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/d5ec1a6bfece4461aca4245d1ba015ac.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/d5ec1a6bfece4461aca4245d1ba015ac"}}, "title": "KRAS G12C Mutant Non-Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demographics and Survival Data From the National Swedish Lung Cancer Registry.", "authors": [{"family": "Isaksson", "given": "Johan", "initials": "J"}, {"family": "Berglund", "given": "Anders", "initials": "A"}, {"family": "Louie", "given": "Karly", "initials": "K"}, {"family": "Will\u00e9n", "given": "Linda", "initials": "L"}, {"family": "Hamidian", "given": "Arash", "initials": "A"}, {"family": "Edsj\u00f6", "given": "Anders", "initials": "A"}, {"family": "Enlund", "given": "Fredrik", "initials": "F"}, {"family": "Planck", "given": "Maria", "initials": "M"}, {"family": "Vikstr\u00f6m", "given": "Anders", "initials": "A"}, {"family": "Johansson", "given": "Mikael", "initials": "M"}, {"family": "Hallqvist", "given": "Andreas", "initials": "A"}, {"family": "Wagenius", "given": "Gunnar", "initials": "G"}, {"family": "Botling", "given": "Johan", "initials": "J"}], "type": "journal article", "published": "2023-09-00", "journal": {"title": "Clin Lung Cancer", "issn": "1938-0690", "volume": "24", "issue": "6", "pages": "507-518", "issn-l": null}, "abstract": "Real-world data on demographics related to KRAS mutation subtypes are crucial as targeted drugs against the p.G12C variant have been approved.\n\nWe identified 6183 NSCLC patients with reported NGS-based KRAS status in the Swedish national lung cancer registry between 2016 and 2019. Following exclusion of other targetable drivers, three cohorts were studied: KRAS-G12C (n = 848), KRAS-other (n = 1161), and driver negative KRAS-wild-type (wt) (n = 3349).\n\nThe prevalence of KRAS mutations and the p.G12C variant respectively was 38%/16% in adenocarcinoma, 28%/13% in NSCLC-NOS and 6%/2% in squamous cell carcinoma. Women were enriched in the KRAS-G12C (65%) and KRAS-other (59%) cohorts versus KRAS-wt (48%). A high proportion of KRAS-G12C patients in stage IV (28%) presented with CNS metastasis (vs. KRAS-other [19%] and KRAS-wt [18%]). No difference in survival between the mutation cohorts was seen in stage I-IIIA. In stage IV, median overall survival (mOS) from date of diagnosis was shorter for KRAS-G12C and KRAS-other (5.8 months/5.2 months) vs. KRAS wt (6.4 months). Women had better outcome in the stage IV cohorts, except in KRAS-G12C subgroup where mOS was similar between men and women. Notably, CNS metastasis did not impact survival in stage IV KRAS-G12C, but was associated with poorer survival, as expected, in KRAS-other and KRAS-wt.\n\nThe KRAS p.G12C variant is a prevalent targetable driver in Sweden and significantly associated with female sex and presence of CNS metastasis. We show novel survival effects linked to KRAS p.G12C mutations in these subgroups with implications for clinical practice.", "doi": "10.1016/j.cllc.2023.05.002", "pmid": "37296038", "labels": [], "xrefs": [{"db": "pii", "key": "S1525-7304(23)00096-7"}], "notes": [], "created": "2026-08-21T11:16:45.854Z", "modified": "2026-08-21T11:16:45.867Z"}, {"entity": "publication", "iuid": "797a03283c7a4019ae8122f96d7ce236", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/797a03283c7a4019ae8122f96d7ce236.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/797a03283c7a4019ae8122f96d7ce236"}}, "title": "Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer.", "authors": [{"family": "Yu", "given": "Hui", "initials": "H"}, {"family": "Brustugun", "given": "Odd Terje", "initials": "OT"}, {"family": "Ekman", "given": "Simon", "initials": "S"}, {"family": "Botling", "given": "Johan", "initials": "J"}, {"family": "La Fleur", "given": "Linnea", "initials": "L"}, {"family": "Micke", "given": "Patrick", "initials": "P"}, {"family": "Solberg", "given": "Steinar", "initials": "S"}, {"family": "Berglund", "given": "Anders", "initials": "A"}, {"family": "Rivard", "given": "Christopher", "initials": "C"}, {"family": "Hirsch", "given": "Fred R", "initials": "FR"}], "type": "journal article", "published": "2021-07-00", "journal": {"title": "Clin Lung Cancer", "issn": "1938-0690", "volume": "22", "issue": "4", "pages": "e555-e562", "issn-l": null}, "abstract": "Recently, anti-programmed cell death 1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) immunotherapies have yielded promising outcomes for patients with advanced non-small cell lung cancer (NSCLC) and led to great interest in applying these agents to treat resectable early-stage NSCLC. The objective of our study was to evaluate PD-L1 protein expression in resectable early-stage NSCLC specimens from a large Northern European cohort, examine the relationship to clinical characteristics, and demonstrate the prognostic role in resected NSCLC.\n\nA large cohort of 875 NSCLC tumors consisted of 337 patients from Sweden and 538 patients from Norway was studied. All the patients had undergone pulmonary resection, and most patients had had early-stage NSCLC. PD-L1 protein expression was assessed by immunohistochemistry using the Dako PD-L1 22C3 pharmDx kit. The tumor proportion score for PD-L1 protein expression was compared with comprehensive demographic and clinicopathologic data.\n\nThe overall prevalence of PD-L1 protein expression in the resectable NSCLC cohort was 9.5% at a tumor proportion score cutoff of \u2265 50%. Stage I NSCLC had lower PD-L1 expression compared with that of the other stages (P = .0012). PD-L1 expression correlated with wild-type EGFR gene expression (P = .0156) and mutated KRAS gene expression (P = .0004). No significant association was found between PD-L1 expression and mortality after multivariable adjustment for clinical characteristics, although the survival curves showed PD-L1 expression significantly correlated with a poor prognosis in the total NSCLC cohort and in the adenocarcinoma subgroup.\n\nPD-L1 expression in the present large cohort of resectable NSCLC was relatively low compared with data from clinical trials of advanced NSCLC. PD-L1 expression correlated positively with tumor stage, wild-type EGFR, and KRAS mutation. PD-L1 expression was not found as an independent prognostic factor in the present study. These findings could be important in the future when evaluating the role of anti-PD-1/PD-L1 immunotherapy in the setting of neoadjuvant or adjuvant trials for early-stage resectable NSCLC.", "doi": "10.1016/j.cllc.2020.09.018", "pmid": "33214079", "labels": [], "xrefs": [{"db": "pii", "key": "S1525-7304(20)30299-0"}], "notes": [], "created": "2026-08-21T11:16:43.958Z", "modified": "2026-08-21T11:16:44.003Z"}], "created": "2026-08-21T11:16:43.970Z", "modified": "2026-08-21T11:16:43.970Z"}